Does the presence of Atypical Intraductal Proliferation (AIP) on prostate needle biopsy influence your risk stratification?

While intraductal carcinoma is not in the classic risk groupings, many believe this represents a high-risk feature. Does AIP leave you concerned for undetected intraductal carcinoma of the prostate or represent a future predictor for an intraductal component to be present?